By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A new study on Biotechnology is now available. According to news reporting from Wilmington, Delaware, by NewsRx editors, the research stated, "The care of patients with respiratory diseases has improved vastly in the past 50 years. In spite of that, there are still massive challenges that have not been resolved."
The news correspondents obtained a quote from the research from Thomas Jefferson University, "Although the incidence of tuberculosis has decreased in the developed world, it is still a significant public health problem in the rest of the world. There are still over 2 million deaths annually from tuberculosis, with most of these occurring in the developing world. Even with the development of new pharmaceuticals to treat tuberculosis, there is no indication that the disease will be eradicated. Respiratory syncytial virus, severe acute respiratory syndrome, and pertussis are other respiratory infectious diseases with special problems of their own, from vaccine development to vaccine coverage. Asthma, one of the most common chronic diseases in children, still accounts for significant mortality and morbidity, as well as high health care costs worldwide. Even in developed countries such as the USA, there are over 4,000 deaths per year. Severe asthma presents a special problem, but the question is whether there can be one treatment pathway for all patients with severe asthma. Severe asthma is a heterogeneous disease with many phenotypes and endotypes. The gene for cystic fibrosis was discovered over 24 years ago. The promise of gene therapy as a cure for the disease has fizzled out, and while new antimicrobials and other pharmaceuticals promise improved longevity and better quality of life, the average life span of a patient with cystic fibrosis is still at about 35 years."
According to the news reporters, the research concluded: "What are the prospects for gene therapy in the twenty-first century? Autoimmune diseases of the lung pose a different set of challenges, including the development of biomarkers to diagnose and monitor the disease and biological modulators to treat the disease."
For more information on this research see: Unmet Needs in Respiratory Diseases. Clinical Reviews in Allergy & Immunology, 2013;45(3):303-313. Clinical Reviews in Allergy & Immunology can be contacted at: Humana Press Inc, 999 Riverview Drive Suite 208, Totowa, NJ 07512, USA (see also Biotechnology).
Our news journalists report that additional information may be obtained by contacting C. Chang, Thomas Jefferson University, Div Allergy & Immunol, Wilmington, DE 19803, United States.
Keywords for this news article include: Biotechnology, Asthma, Delaware, Wilmington, Gene Therapy, United States, Bioengineering, Bacterial Vaccines, Bronchial Diseases, Biological Products, Respiratory Disease, Tuberculosis Vaccines, Gram-Positive Bacteria, Immune System Diseases, Mycobacterium Infections, North and Central America, Obstructive Lung Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC